[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nodule-solitary-pulmonary\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nodule-solitary-pulmonary":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100345212","biomarkers-for-risk-stratification-in-lung-cancer-100345212",false,"NCT03774758","Biomarkers for Risk Stratification in Lung Cancer","Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening","Inclusion Criteria:\n\n* Age ≥ 40 years\n* Ability to understand and provide written informed consent\n* Willingness to comply with study protocols and provide blood samples.\n* Willingness to complete 3-year clinical follow up\n\nExclusion Criteria:\n\n* Active non-cutaneous malignancy within the past 5 years as per medical record or patient report.\n* Exclusion criteria for possible follow-up visit blood draw:\n* Anemia - measured by hematocrit level of less than 30%, measured after the first blood draw.\n* Malnourishment - determined by BMI less than 19. If subject has BMI greater or equal to 19, but has a history of malnourishment, study staff will measure albumin level of subject's blood after initial blood draw. Albumin level must be greater than 2.5 mg per deciliter, or subject will be excluded.\n* Severe Chronic Obstructive Pulmonary Disease (COPD) - defined by Gold Stage IV.\n* Unstable heart conditions - defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy, or history of complications because of previous blood donation.\n* Liver cirrhosis.","ALL","40 Years",{"count":19,"type":20},590,"ESTIMATED","3 Years","OBSERVATIONAL","This is a prospective observational study that will follow patients who undergo lung cancer screening at the San Francisco VA Medical Center, University of California, San Francisco (UCSF) Medical Center, and the San Francisco General Hospital. The proposed study will comprise of two primary populations to determine the ctDNA assay performance in a variety of clinical settings.",[25,26],"Nodule Solitary Pulmonary","Non-small Cell Lung Cancer",[28,29,30,31,32],"Lung cancer screening","Biomarkers of lung cancer","Circulating tumor DNA","Low dose computed tomography of lung","Pulmonary nodule","RECRUITING","2026-06-01",{"date":36,"type":37},"2026-06-04","ACTUAL",{"date":39,"type":37},"2017-12-17",{"date":41,"type":20},"2030-12-31",{"name":43,"class":44},"University of California, San Francisco","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100639916","non-invasive-malignancy-classifiers-using-blood-biomarkers-for-lung-nodule-evaluation-100639916","NCT07623473","Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE | Non-Invasive Malignancy Classifiers Using Blood-Biomarkers for Lung Nodule Evaluation","NIMBLE","Inclusion Criteria:\n\n* Patients with a newly detected IPN suspected of lung cancer referred to the infiltrate unit\n* Having signed informed consent\n\nExclusion Criteria:\n\n* Active cancer, excluding non-melanoma skin cancer\n* Comorbidities that exclude the patient from clinical follow-up and final diagnosis",true,{"count":56,"type":20},1800,"The goal of the NIMBLE study is to evaluate blood-based biomarkers for lung cancer risk prediction in patients referred with a lung nodule.\n\nEach blood biomarker will be evaluated for descriminating malignant from benign lung nodules alone and in combination with other blood biomarkers, patient characteristics and radiological features.",[59,60],"Lung Cancer (Diagnosis)","Nodule, Solitary Pulmonary",[62,63,64,65,66],"Biomarkers","Lung nodule","Fragmentomics","Methylome","Cell-free DNA","2026-05-29",{"date":69,"type":37},"2026-06-03",{"date":71,"type":37},"2024-05-22",{"date":73,"type":20},"2028-02-01",{"name":75,"class":44},"Herlev and Gentofte Hospital",1]